Organon & Co (OGN)
15.28
+0.39
(+2.62%)
USD |
NYSE |
Nov 22, 16:00
15.35
+0.07
(+0.46%)
Pre-Market: 20:00
Organon Cash from Investing (Quarterly): -75.00M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -75.00M |
| June 30, 2024 | -46.00M |
| March 31, 2024 | -96.00M |
| December 31, 2023 | -81.00M |
| September 30, 2023 | -55.00M |
| June 30, 2023 | -70.00M |
| March 31, 2023 | -54.00M |
| December 31, 2022 | -61.00M |
| September 30, 2022 | -213.00M |
| June 30, 2022 | -83.00M |
| Date | Value |
|---|---|
| March 31, 2022 | -63.00M |
| December 31, 2021 | -489.00M |
| September 30, 2021 | -61.00M |
| June 30, 2021 | -249.00M |
| March 31, 2021 | -38.00M |
| December 31, 2020 | -118.00M |
| September 30, 2020 | -50.00M |
| June 30, 2020 | -41.00M |
| March 31, 2020 | -49.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-489.00M
Minimum
Dec 2021
-38.00M
Maximum
Mar 2021
-104.84M
Average
-63.00M
Median
Mar 2022
Cash from Investing (Quarterly) Benchmarks
| ResMed Inc | 2.146M |
| TG Therapeutics Inc | -9.334M |
| Sage Therapeutics Inc | 81.05M |
| Applied Therapeutics Inc | 0.00 |
| Vor Biopharma Inc | -0.034M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 141.00M |
| Cash from Financing (Quarterly) | -78.00M |
| Free Cash Flow | 646.00M |
| Free Cash Flow Per Share (Quarterly) | 0.2502 |
| Free Cash Flow to Equity (Quarterly) | -28.00M |
| Free Cash Flow to Firm (Quarterly) | 283.52M |
| Free Cash Flow Yield | 16.37% |